pipeline-prospector-insert-v1
X

Find Ophthalmology Drugs in Phase I/II Clinical Development in GERMANY

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type

            Companies

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): EYS606

            Therapeutic Area: Ophthalmology

            Highest Development Status: Phase I/ Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Boehringer Ingelheim Venture Fund

            Deal Size: $30.0 million Upfront Cash: Undisclosed

            Deal Type: Series B Financing January 08, 2020

            Details:

            The company will use the funds to continue the development of its clinical lead candidate EYS606 for the treatment of chronic non-infectious uveitis (NIU), including the launch of its Electro Study.